Abstract
Purpose
Proinflammatory and anti-inflammatory cytokines may play a pivotal role in cerebral inflammation, which is implicated in the development of brain injury. Systemic cytokine release is mediated by the sympathetic nervous system and catecholamines. The aim of this study was to investigate which parameters, among plasma levels of interleukin-1β (IL-1β), interleukin-6 (IL-6), interleukin-10 (IL-10), and tumor necrosis factor alpha (TNF-α) and the levels of the catecholamines, epinephrine and norepinephrine, contribute to the clinical outcome in acute stroke patients.
Methods
Thirty-seven acute stroke patients (ischemic, n = 19; hemorrhagic, n = 18) were enrolled. All of them were admitted to our hospital within 8 h after stroke onset. Neurological status was evaluated by a modified National Institute of Health Stroke Scale (mNIHSS) on admission and by a modified Rankin Scale (mRS) at 1 month. An mRS score of 3 or more at 1 month was considered to indicate poor outcome. Serum samples for the cytokine and catecholamine measurements were collected on admission. Plasma levels of IL-1β, IL-6, IL-10, and TNF-α were determined by an enzyme-linked immunosorbent assay (ELISA) method and epinephrine and norepinephrine concentrations were determined by high-performance liquid chromatography with electrochemical detection (HPLC-EC).
Results
In the ischemic stroke patients, poor outcome was noted in 9 (47%). There were no significant differences in cytokine or catecholamine concentrations between patients with poor and good outcomes, and there was no association between clinical outcome and cytokine and catecholamine concentrations. In the hemorrhagic stroke patients, poor outcome was noted in 10 (56%). IL-6 and IL-10 levels were higher in patients with poor outcome. On logistic regression analysis, higher values of IL-6 were significantly associated with clinical outcome at 1 month (odds ratio [OR], 1.25; 95% confidence interval [CI], 1.02–1.54).
Conclusion
In ischemic stroke, plasma cytokines and catecholamines were not predictors of neurological outcome at 1 month. In hemorrhagic stroke, high levels of IL-6 in the early phase indicated a poor neurological outcome.
Similar content being viewed by others
References
Becker KJ. Inflammation and acute stoke. Curr Opin Neurol. 1998;11:45–49.
Vila N, Filella X, Deulofeu R, Ascaso C, Abellana R, Chamorro A. Cytokine-induced inflammation and long-term stroke functional outcome. J Neurol Sci. 1999;162:185–188.
Woiciechowsky C, Schoning B, Lanksch WR, Volk HD, Docke WD. Mechanisms of brain-mediated systemic anti-inflammatory syndrome causing immunodepression. J Mol Med. 1999;77:769–780.
Liu T, McDonnell PC, Young PR, White RF, Siren AL, Hallenbeck JM, Barone FC, Feuerstein GZ. Interleukin 1β mRNA expression in ischemic rat cortex. Stroke. 1993;24:1746–1752.
Wang X, Yue T-L, Young PR, Barone FC, Feuerstein GZ. Expression of interleukin-6, c-fos and zif268 mRNA in rat ischemic cortex. J Cereb Blood Flow Metab. 1995;15:166–171.
Liu T, Clark RK, McDonnell PC, Young PR, White RF, Barone FC, Feuerstein GZ. Tumor necrosis factor-α in ischemic neurons. Stroke. 1994;25:1481–1488.
Fassbender K, Rossol S, Kammer T, Daffertshofer M, Wirth S, Dollman M, Hennerici M. Proinflammatory cytokines in serum of patients with acute cerebral damage and outcome of disease. J Neurol Sci. 1994;122:135–139.
Dziedzic T, Bartus S, Klimkowicz A, Motyl M, Slowik A, Szczudlik A. Intracranial hemorrhage triggers interleukin-6 and interleukin-10 release in blood. Stroke. 2002;33:2334–2335.
Smith CJ, Emsley HCA, Gavin CM, Georgiou RF, Vail A, Barberan EM, Zoppo GJ, Hallenbeck JM, Rothwell NJ, Hopkins SJ, Tyrrell PJ. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischemic stoke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol. 2004;15:4:2.
Tarkowski E, Rosengren L, Blomstrand C, Wikkelso C, Jensen C, Ekholm S, Tarkowski A. Intrathecal release of pro-and anti-inflammatory cytokines during stroke. Clin Exp Immunol. 1997;110:492–499.
Perini F, Morra M, Alecci M, Galloni E, Marchi M, Toso V. Temporal profile of serum anti-inflammatory and pro-inflammatory interleukins in acute stroke patients. Neurol Sci. 2001;22:289–296.
Vila N, Castillo J, Davalos A, Esteve A, Planas A, Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke. 2003;34:671–675.
Marz P, Cheng JG, Gadient R, Patterson P, Stoyan T, Otten U, Rose-John S. Sympathetic neurons can produce and respond to IL-6. Proc Natl Acad Sci U S A. 1998;95:3251–3256.
Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzer C, Schoening B, Gloeckner F, Lanksch WR, Volk HD, Doecke WD. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med. 1998;4:808–813.
Myers MG, Norris JW, Hachinski VC, Sole MJ. Plasma norepinephrine in stroke. Stroke. 1981;12:200–204.
Naredi S, Lambert G, Eden E, Zall S, Runnerstam M, Rydenhag B, Friberg P. Increased sympathetic nervous activity in patients with nontraumatic subarachnoid hemorrhage. Stroke. 2001;31:901–906.
Benedict CR, Phil D, Loach AB. Sympathetic nervous system activity in patients with subarachnoid hemorrhage. Stroke. 1978;9:237–244.
Meyer JS, Stoica E, Pascu I, Shimazu K, Hartmann A. Catecholamine concentrations in CSF and plasma of patients with cerebral infarction and hemorrhage. Brain. 1973;96:277–288.
Baron JC. Perfusion thresholds in human ischemia: historical perspective and therapeutic implications. Cerebrovasc Dis. 2001;11(Suppl 1):2–8.
Lyden PD, Lu M, Levine SR, Brott TG, Broderick J, the NINDS rtPA Stroke Study Group. A modified National Institutes of Health Stroke Scale for use in stroke clinical trials. Preliminary reliability and validity. Stroke. 2001;32:1310–1317.
van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijin J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke. 1988;19:604–607.
Vila N, Castillo J, Davalos A, Esteve A, Chamorro A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke. 2003;31:2325–2329.
McKeating EG, Andrews PJD, Signorini DF, Mascia L. Transcranial cytokine gradients in patients requiring intensive care after brain injury. Br J Anaesth. 1997;78:520–523.
Mazzotta G, Sarchielli P, Caso V, Paciaroni M, Floridi A, Gallai V. Different cytokine levels in thrombolysis patients as predictors for clinical outcome. Eur J Neurol. 2004;11:377–381.
Intiso D, Zarrelli MM, Lagioia G, Rienzo FD, Ambrosio CCD, Simone P, Tonali P, Cioffi RP. Tumor necrosis factor alpha serum levels and inflammatory response in acute ischemic stroke patients. Neurol Sci. 2003;24:390–396.
Ferrarese C, Mascarucci P, Zoia C, Cavarretta R, Frigo M, Begni B, Sarinella F, Frattola L, Simoni MGD. Increased cytokine release from peripheral blood cells after acute stroke. J Cereb Blood Flow Metab. 1999;19:1004–1009.
Planz G, Wiethold G, Appel E, Bohmer D, Palm D, Grobecker H. Correlation between increased dopamine-beta-hydroxylase activity and catecholamine concentration in plasma: determination of acute changes in sympathetic activity in man. Eur J Clin Pharmacol. 1975;8:181–188.
Cryer PE. Physiology and pathophysiology of the human sympathoadrenal neuroendocrine system. N Engl J Med. 1980;303:436–444.
Author information
Authors and Affiliations
About this article
Cite this article
Oto, J., Suzue, A., Inui, D. et al. Plasma proinflammatory and anti-inflammatory cytokine and catecholamine concentrations as predictors of neurological outcome in acute stroke patients. J Anesth 22, 207–212 (2008). https://doi.org/10.1007/s00540-008-0639-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00540-008-0639-x